Results for tag: "Catenin Beta 1"

Catenin Beta 1 (CTNNB1) is a protein that plays a role in the regulation of cell growth and differentiation. It is a key component of the Wnt signaling pathway, which is involved in the development of many types of cancer. CTNNB1 is a promising target for oncology drugs, as it has been linked to a variety of cancers, including colorectal, breast, and ovarian cancer. CTNNB1-targeted drugs are designed to block the activity of the protein, thereby preventing cancer cells from growing and spreading. These drugs are being developed to treat a variety of cancers, including those that are resistant to traditional treatments. Several companies are developing CTNNB1-targeted drugs, including AstraZeneca, Merck, and Pfizer. These companies are working to develop drugs that can be used to treat a variety of cancers, including those that are resistant to traditional treatments. Additionally, several biotech companies are researching CTNNB1-targeted drugs, including AbbVie, Celgene, and Novartis. Show Less Read more